SEC Form 4 · accession 0001104659-17-053434
Cardiff Oncology, Inc. · CRDF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Erlander
Officer — Chief Scientific Officer
Period of report
Aug 22, 2017
Accepted (ET)
Aug 24, 2017 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001213037
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $0.85 | Aug 22, 2017 | A | 385,000 | A | — | Aug 22, 2027 | Common Stock | 385,000 | 1,110,000 | D |
Explanation of responses
- F148,125 vest immediately upon grant and 48,125 vest quarterly for 7 quarters following the date of grant.